Company profile: Revive Therapeutics
1.1 - Company Overview
Company description
- Provider of therapeutics and diagnostics, including Bucillamine, an oral thiol-based drug being developed for COVID-19, long COVID, other infectious diseases, and rare inflammatory disorders; psilocybin-based therapeutics for mental illnesses and substance use disorders; CBD therapeutics for autoimmune hepatitis and transplant injury prevention; and a point-of-care lateral flow test for post-COVID-19 conditions.
Products and services
- Revive LC POC Lateral Flow Test Kit: Point-of-care in vitro diagnostic device that detects post-COVID-19 conditions using blood biomarkers for identification of long COVID
- Psilocybin-based Therapeutics: Therapeutics using psilocybin to treat mental illnesses such as depression and anxiety, and substance use disorders like methamphetamine use disorder
- Bucillamine: Oral thiol-based drug under development to treat COVID-19, long COVID, other infectious diseases, and rare inflammatory disorders
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Revive Therapeutics
Cellestis
HQ: Australia
Website
- Description: Provider of QuantiFERON products for medical diagnosis and scientific research, utilizing a patented whole blood method to detect cell-mediated immune responses.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cellestis company profile →
Diagnostic Hybrids
HQ: United States
Website
- Description: Provider of cellular and molecular diagnostic kits and systems for detecting respiratory diseases, herpes infections, thyroid function, and other disease markers. Offers the D3 FastPoint L-DFA influenza A/B identification kit; Vitros Integrated, Chemistry, and Immunoassay Systems with broad, waterless testing menus; Ortho Vision Swift analyzer for automated donor typing; and Lyra real-time PCR assays that simplify sample processing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Diagnostic Hybrids company profile →
Friz Biochem
HQ: Germany
Website
- Description: Provider of advanced electronic biochips and offerings integrating the complete workflow of molecular diagnostics; privately held, founded in October 2004 and based in Neuried near Munich.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Friz Biochem company profile →
Cerexa
HQ: United States
Website
- Description: Provider of novel anti-infective therapies for serious and life-threatening infections; develops a portfolio of treatments including Ceftaroline Acetate/Ceftaroline, an injectable cephalosporin used for bacterial infections.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cerexa company profile →
Microgen Bioproducts
HQ: United Kingdom
Website
- Description: Provider of diagnostic products for clinical, food, and environmental testing, with a portfolio for clinical laboratories including microbiology diagnostics; engages in the development, manufacture, distribution, and marketing of products.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Microgen Bioproducts company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Revive Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Revive Therapeutics
2.2 - Growth funds investing in similar companies to Revive Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Revive Therapeutics
4.2 - Public trading comparable groups for Revive Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →